Biomarkers for therapy selection in metastatic urothelial cancer

Tomi Jun, Jonathan Anker, Matthew D. Galsky

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The treatment of metastatic urothelial cancer (mUC) has been transformed by recent progress in clinical trials and drug development. There are now three therapeutic classes with proven benefits in mUC: chemotherapy, immunotherapy, and targeted therapy. The optimal sequence and combination of these classes remain to be defined. Biomarker development is essential to guide treatment selection at each therapeutic juncture. Two biomarkers, programmed death-ligand 1 expression and fibroblast growth factor receptor alterations, have been incorporated into the mUC treatment paradigm thus far. This review discusses predictive biomarkers in development and their potential to influence mUC treatment selection moving forward.

Original languageEnglish
Article number1
JournalJournal of Cancer Metastasis and Treatment
StatePublished - 2022


  • Metastatic urothelial cancer
  • antibody-drug conjugates
  • biomarkers
  • chemotherapy
  • immunotherapy
  • targeted therapy


Dive into the research topics of 'Biomarkers for therapy selection in metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this